Cargando…

Clinical Prediction Model for Time in Therapeutic Range While on Warfarin in Newly Diagnosed Atrial Fibrillation

BACKGROUND: Though warfarin has historically been the primary oral anticoagulant for stroke prevention in newly diagnosed atrial fibrillation (AF), several new direct oral anticoagulants may be preferred when anticoagulation control with warfarin is expected to be poor. This study developed a predic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Williams, Brent A., Evans, Michael A., Honushefsky, Ashley M., Berger, Peter B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721868/ https://www.ncbi.nlm.nih.gov/pubmed/29025746 http://dx.doi.org/10.1161/JAHA.117.006669

Ejemplares similares

Time in Therapeutic Range and Outcomes After Warfarin Initiation in Newly Diagnosed Atrial Fibrillation Patients With Renal Dysfunction
por: Szummer, Karolina, et al.
Publicado: (2017)

Age is associated with time in therapeutic range for warfarin therapy in patients with atrial fibrillation
por: Marcatto, Leiliane Rodrigues, et al.
Publicado: (2016)

Patients’ time in therapeutic range on warfarin among atrial fibrillation patients in Warfarin Medication Therapy Adherence Clinic
por: Lee, Siew Ling, et al.
Publicado: (2021)

Time in Therapeutic Range Using a Nomogram for Dose Adjustment of Warfarin in Patients on Hemodialysis With Atrial Fibrillation
por: Defoe, Kimberly, et al.
Publicado: (2021)

Reduced dose direct oral anticoagulants compared with warfarin with high time in therapeutic range in nonvalvular atrial fibrillation
por: Jansson, M., et al.
Publicado: (2023)

Atrial fibrillation bleeding risk and prediction while treated with direct oral anticoagulants in warfarin‐naïve or warfarin‐experienced patients
por: Perino, Alexander C., et al.
Publicado: (2022)

Lower dose direct oral anticoagulation or warfarin in atrial fibrillation. Which one is the best when time on therapeutic range information is available?
por: Luojus, A, et al.
Publicado: (2023)

Alternative Calculations of Individual Patient Time in Therapeutic Range While Taking Warfarin: Results From the ROCKET AF Trial
por: Singer, Daniel E., et al.
Publicado: (2015)

Warfarin and atrial fibrillation: from ideal to real the warfarin affaire
por: Molteni, Mauro, et al.
Publicado: (2014)

Disease understanding in patients newly diagnosed with atrial fibrillation
por: Kaufman, Brystana G, et al.
Publicado: (2018)

The use of warfarin in veterans with atrial fibrillation
por: Bravata, Dawn M, et al.
Publicado: (2004)

Hospital Admissions, Costs, and 30-Day Readmissions Among Newly Diagnosed Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran Etexilate or Warfarin
por: Fonseca, Eileen, et al.
Publicado: (2015)

Direct oral anti-Xa anticoagulants versus warfarin in newly diagnosed atrial fibrillation and CKD: the Korean National Health Insurance Data
por: Kee, Youn Kyung, et al.
Publicado: (2023)

The importance of mean time in therapeutic range for complication rates in warfarin therapy of patients with atrial fibrillation: A systematic review and meta-regression analysis
por: Vestergaard, Anne Sig, et al.
Publicado: (2017)

The awareness, efficacy, safety, and time in therapeutic range of warfarin in the Turkish population: WARFARIN-TR
por: Çelik, Ahmet, et al.
Publicado: (2016)

Newly Diagnosed Atrial Fibrillation in Acute Myocardial Infarction
por: Obayashi, Yuki, et al.
Publicado: (2021)

An Automated Clinical Alert System for Newly-Diagnosed Atrial Fibrillation
por: Cook, David A., et al.
Publicado: (2015)

Time in therapeutic range, quality of life and treatment satisfaction of patients on long-term warfarin for non-valvular atrial fibrillation: a cross-sectional study
por: Ng, Diana-Leh-Ching, et al.
Publicado: (2020)

Stroke Severity and Outcomes in Patients With Newly Diagnosed Atrial Fibrillation
por: Watanabe, Kotaro, et al.
Publicado: (2021)

Physician–Pharmacist Collaborative Clinic Model to Improve Anticoagulation Quality in Atrial Fibrillation Patients Receiving Warfarin: An Analysis of Time in Therapeutic Range and a Nomogram Development
por: Wang, Na, et al.
Publicado: (2021)

Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation
por: Camm, A John, et al.
Publicado: (2017)

Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation
por: Nelson, Winnie W., et al.
Publicado: (2014)

How good is time-in-therapeutic-range defined warfarin treatment compared to standard dose direct oral anticoagulants? Incidence of stroke in atrial fibrillation in a nationwide registry study
por: Lehto, M, et al.
Publicado: (2023)

Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States
por: Jain, Rahul, et al.
Publicado: (2018)

The Comparison of Therapeutic Efficacy Between Dabigatran Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation
por: Li, Hongxia, et al.
Publicado: (2021)

Variability in the Calculation of Time in Therapeutic Range for the Quality Control Measurement of Warfarin
por: Siddiqui, Safia, et al.
Publicado: (2018)

Identification of environmental and genetic factors that influence warfarin time in therapeutic range
por: Botton, Mariana R., et al.
Publicado: (2020)

Is the Median Hourly Ambulatory Heart Rate Range Helpful in Stratifying Mortality Risk among Newly Diagnosed Atrial Fibrillation Patients?
por: Chen, Hsing-Yu, et al.
Publicado: (2021)

Discontinuation risk comparison among ‘real-world’ newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban
por: Lip, Gregory Y. H., et al.
Publicado: (2018)

Required warfarin dose and time in therapeutic range in patients with diagnosed Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH)
por: Wen, Xuerong, et al.
Publicado: (2021)

Chinese stroke patients with atrial fibrillation used Robert's age-adjusted warfarin loading protocol obtained good INR results within therapeutic range
por: Luo, Weiliang, et al.
Publicado: (2023)

Safety and Effectiveness of Direct Oral Anticoagulants vs. Warfarin in Patients With Atrial Fibrillation and Endoscopy-Diagnosed Peptic Ulcer
por: Wang, Chun-Li, et al.
Publicado: (2021)

Outcomes Associated With Oral Anticoagulants Plus Antiplatelets in Patients With Newly Diagnosed Atrial Fibrillation
por: Fox, Keith A. A., et al.
Publicado: (2020)

Initiation and Persistence with Warfarin Therapy in Atrial Fibrillation According to Ethnicity
por: Hansen, Carolina Malta, et al.
Publicado: (2012)

Improving outpatient warfarin use for hospitalized patients with atrial fibrillation
por: Touchette, Daniel R., et al.
Publicado: (2008)

Dabigatran Versus Warfarin for Direct Current Cardioversion in Atrial Fibrillation
por: Benamer, Sufyan, et al.
Publicado: (2016)

Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation
por: Christersson, Christina, et al.
Publicado: (2019)

NOACs vs. Warfarin for Stroke Prevention in Nonvalvular Atrial Fibrillation
por: Patel, Priya, et al.
Publicado: (2017)

Characteristics of warfarin under-prescription in older adults with atrial fibrillation
por: Rashid, Sana, et al.
Publicado: (2021)

Risk of mortality in a cohort of patients newly diagnosed with chronic atrial fibrillation
por: Ruigómez, Ana, et al.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_f85shn6nbgddd00qv0i8897p3a